Previous close | 93.72 |
Open | 95.88 |
Bid | 96.86 x 100 |
Ask | 97.00 x 100 |
Day's range | 95.00 - 97.44 |
52-week range | 36.90 - 98.82 |
Volume | |
Avg. volume | 1,370,848 |
Market cap | 11.855B |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.78 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 103.94 |
AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
On April 29, 2024, Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), sold 1,238 shares of the company.
On April 29, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), sold 4,084 shares of the company.